The COVID-19 in athletes (COVA) study: a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes. Issue 1 (31st December 2023)
- Record Type:
- Journal Article
- Title:
- The COVID-19 in athletes (COVA) study: a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes. Issue 1 (31st December 2023)
- Main Title:
- The COVID-19 in athletes (COVA) study: a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes
- Authors:
- Rasmusen, Hanne Kruuse
Aarøe, Mikkel
Madsen, Christoffer Valdorff
Gudmundsdottir, Helga Lillian
Mertz, Kenneth Hudlebusch
Mikkelsen, Astrid Duus
Dall, Christian Have
Brushøj, Christoffer
Andersen, Jesper Løvind
Vall-Lamora, Maria Helena Dominguez
Bovin, Ann
Magnusson, S. Peter
Thune, Jens Jakob
Pecini, Redi
Pedersen, Lars - Abstract:
- ABSTRACT: Background: COVID-19 can cause cardiopulmonary involvement. Physical activity and cardiac complications can worsen prognosis, while pulmonary complications can reduce performance. Aims: To determine the prevalence and clinical implications of SARS-CoV-2 cardiopulmonary involvement in elite athletes. Methods: An observational study between 1 July 2020 and 30 June 2021 with the assessment of coronary biomarkers, electrocardiogram, echocardiography, Holter-monitoring, spirometry, and chest X-ray in Danish elite athletes showed that PCR-tested positive for SARS-CoV-2. The cohort consisted of male football players screened weekly (cohort I) and elite athletes on an international level only tested if they had symptoms, were near-contact, or participated in international competitions (cohort II). All athletes were categorized into two groups based on symptoms and duration of COVID-19: Group 1 had no cardiopulmonary symptoms and duration ≤7 days, and; Group 2 had cardiopulmonary symptoms or disease duration >7 days. Results: In total 121 athletes who tested positive for SARS-CoV-2 were investigated. Cardiac involvement was identified in 2/121 (2%) and pulmonary involvement in 15/121 (12%) participants. In group 1, 87 (72%), no athletes presented with signs of cardiac involvement, and 8 (7%) were diagnosed with radiological COVID-19-related findings or obstructive lung function. In group 2, 34 (28%), two had myocarditis (6%), and 8 (24%) were diagnosed with radiologicalABSTRACT: Background: COVID-19 can cause cardiopulmonary involvement. Physical activity and cardiac complications can worsen prognosis, while pulmonary complications can reduce performance. Aims: To determine the prevalence and clinical implications of SARS-CoV-2 cardiopulmonary involvement in elite athletes. Methods: An observational study between 1 July 2020 and 30 June 2021 with the assessment of coronary biomarkers, electrocardiogram, echocardiography, Holter-monitoring, spirometry, and chest X-ray in Danish elite athletes showed that PCR-tested positive for SARS-CoV-2. The cohort consisted of male football players screened weekly (cohort I) and elite athletes on an international level only tested if they had symptoms, were near-contact, or participated in international competitions (cohort II). All athletes were categorized into two groups based on symptoms and duration of COVID-19: Group 1 had no cardiopulmonary symptoms and duration ≤7 days, and; Group 2 had cardiopulmonary symptoms or disease duration >7 days. Results: In total 121 athletes who tested positive for SARS-CoV-2 were investigated. Cardiac involvement was identified in 2/121 (2%) and pulmonary involvement in 15/121 (12%) participants. In group 1, 87 (72%), no athletes presented with signs of cardiac involvement, and 8 (7%) were diagnosed with radiological COVID-19-related findings or obstructive lung function. In group 2, 34 (28%), two had myocarditis (6%), and 8 (24%) were diagnosed with radiological COVID-19-related findings or obstructive lung function. Conclusions: These clinically-driven data show no signs of cardiac involvement among athletes who tested positive for SARS-CoV-2 infection without cardiopulmonary symptoms and duration <7 days. Athletes with cardiopulmonary symptoms or prolonged duration of COVID-19 display, exercise-limiting cardiopulmonary involvement. … (more)
- Is Part Of:
- European clinical respiratory journal. Volume 10:Issue 1(2023)
- Journal:
- European clinical respiratory journal
- Issue:
- Volume 10:Issue 1(2023)
- Issue Display:
- Volume 10, Issue 1 (2023)
- Year:
- 2023
- Volume:
- 10
- Issue:
- 1
- Issue Sort Value:
- 2023-0010-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2023-12-31
- Subjects:
- Athletes -- coronavirus -- return-to-sport -- myocarditis -- pulmonary involvement
Lungs -- Diseases -- Periodicals
Respiratory organs -- Diseases -- Periodicals
Lung Diseases
Lungs -- Diseases
Respiratory organs -- Diseases
Europe
Periodicals
Electronic journals
Periodicals
616.24 - Journal URLs:
- https://tandfonline.com/loi/zecr20 ↗
http://www.tandfonline.com/ ↗ - DOI:
- 10.1080/20018525.2022.2149919 ↗
- Languages:
- English
- ISSNs:
- 2001-8525
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24675.xml